» Articles » PMID: 23459797

Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses

Overview
Journal Front Immunol
Date 2013 Mar 6
PMID 23459797
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Complex mechanisms underlying the maintenance of fully functional, proliferative, HIV-1-specific T-cell responses involve processes from early T-cell development through to the final stages of T-cell differentiation and antigen recognition. Virus-specific proliferative CD4 and CD8 T-cell responses, important for the control of infection, are observed in some HIV-1(+) patients during early stages of disease, and are maintained in long-term non-progressing subjects. In the vast majority of HIV-1(+) patients, full immune functionality is lost when proliferative HIV-1-specific T-cell responses undergo a variable progressive decline throughout the course of chronic infection. This appears irreparable despite administration of potent combination antiretroviral therapy, which to date is non-curative, necessitating life-long administration and the development of effective, novel, therapeutic interventions. While a sterilizing cure, involving clearance of virus from the host, remains a primary aim, a "functional cure" may be a more feasible goal with considerable impact on worldwide HIV-1 infection. Such an approach would enable long-term co-existence of host and virus in the absence of toxic and costly drugs. Effective immune homeostasis coupled with a balanced response appropriately targeting conserved viral antigens, in a manner that avoids hyperactivation and exhaustion, may prove to be the strongest correlate of durable viral control. This review describes novel concepts underlying full immune functionality in the context of HIV-1 infection, which may be utilized in future strategies designed to improve upon existing therapy. The aim will be to induce long-term non-progressor or elite controller status in every infected host, through immune-mediated control of viremia and reduction of viral reservoirs, leading to lower HIV-1 transmission rates.

Citing Articles

TCellSI: A novel method for T cell state assessment and its applications in immune environment prediction.

Yang J, Zhang N, Luo T, Yang M, Shen W, Tan Z Imeta. 2024; 3(5):e231.

PMID: 39429885 PMC: 11487559. DOI: 10.1002/imt2.231.


CBX7 is Dualistic in Cancer Progression Based on its Function and Molecular Interactions.

Li J, Ouyang T, Li M, Hong T, Alriashy M, Meng W Front Genet. 2021; 12:740794.

PMID: 34659360 PMC: 8517511. DOI: 10.3389/fgene.2021.740794.


Gut germinal center regeneration and enhanced antiviral immunity by mesenchymal stem/stromal cells in SIV infection.

Weber M, Walters-Laird C, Kol A, Rocha C, Hirao L, Mende A JCI Insight. 2021; 6(12).

PMID: 34014838 PMC: 8262475. DOI: 10.1172/jci.insight.149033.


Insight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infection.

Ayala-Suarez R, Diez-Fuertes F, Calonge E, De La Torre Tarazona H, Gracia-Ruiz de Alda M, Capa L J Clin Med. 2020; 9(8).

PMID: 32751854 PMC: 7464121. DOI: 10.3390/jcm9082452.


Quantification of Viral RNA and DNA Positive Cells in Tissues From Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus Infected Controller and Progressor Rhesus Macaques.

Pahar B, Kuebler D, Rasmussen T, Wang X, Srivastav S, Das A Front Microbiol. 2020; 10:2933.

PMID: 31921088 PMC: 6933296. DOI: 10.3389/fmicb.2019.02933.


References
1.
Betts M, Ambrozak D, Douek D, Bonhoeffer S, Brenchley J, Casazza J . Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol. 2001; 75(24):11983-91. PMC: 116093. DOI: 10.1128/JVI.75.24.11983-11991.2001. View

2.
Ferre A, Hunt P, McConnell D, Morris M, Garcia J, Pollard R . HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol. 2010; 84(21):11020-9. PMC: 2953185. DOI: 10.1128/JVI.00980-10. View

3.
Groves K, Bibby D, Clark D, Isaksen A, Deayton J, Anderson J . Disease Progression in HIV-1-Infected Viremic Controllers. J Acquir Immune Defic Syndr. 2012; 61(4):407-16. PMC: 3736311. DOI: 10.1097/QAI.0b013e318269c414. View

4.
Lane H, Depper J, Greene W, Whalen G, Waldmann T, Fauci A . Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med. 1985; 313(2):79-84. DOI: 10.1056/NEJM198507113130204. View

5.
Addo M, Yu X, Rathod A, Cohen D, Eldridge R, Strick D . Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003; 77(3):2081-92. PMC: 140965. DOI: 10.1128/jvi.77.3.2081-2092.2003. View